Clinical Trial Update: Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating efficacy and safety of multiple doses of IMAB362 in patients with advanced gastroesophageal cancer. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• IMAB362 (zolbetuximab)

Snippet

Sponsor: Ganymed Pharmaceuticals GmbH | Conditions: Solid Tumors | Phase 2 | Status: COMPLETED